Effect of carotid endarterectomy on brain damage markers
Corresponding Author
M. Iłżecki
Chair and Department of Vascular Surgery and Angiology, Medical University of Lublin, Lublin, Poland
M. Iłżecki, Chair and Department of Vascular Surgery and Angiology, Medical University of Lublin, ul. S. Staszica 16, Lublin 20-081, Poland
Tel.: +48 815325707
Fax: +48815325707
e-mail: [email protected]
Search for more papers by this authorJ. Iłżecka
Chair and Department of Vascular Surgery and Angiology, Medical University of Lublin, Lublin, Poland
Independent Neurological Rehabilitation Unit, Medical University of Lublin, Lublin, Poland
Search for more papers by this authorS. Przywara
Chair and Department of Vascular Surgery and Angiology, Medical University of Lublin, Lublin, Poland
Search for more papers by this authorP. Terlecki
Chair and Department of Vascular Surgery and Angiology, Medical University of Lublin, Lublin, Poland
Search for more papers by this authorA. Grabarska
Chair and Department of Biochemistry and Molecular Biology, Medical University of Lublin, Lublin, Poland
Search for more papers by this authorA. Stepulak
Chair and Department of Biochemistry and Molecular Biology, Medical University of Lublin, Lublin, Poland
Search for more papers by this authorT. Zubilewicz
Chair and Department of Vascular Surgery and Angiology, Medical University of Lublin, Lublin, Poland
Search for more papers by this authorCorresponding Author
M. Iłżecki
Chair and Department of Vascular Surgery and Angiology, Medical University of Lublin, Lublin, Poland
M. Iłżecki, Chair and Department of Vascular Surgery and Angiology, Medical University of Lublin, ul. S. Staszica 16, Lublin 20-081, Poland
Tel.: +48 815325707
Fax: +48815325707
e-mail: [email protected]
Search for more papers by this authorJ. Iłżecka
Chair and Department of Vascular Surgery and Angiology, Medical University of Lublin, Lublin, Poland
Independent Neurological Rehabilitation Unit, Medical University of Lublin, Lublin, Poland
Search for more papers by this authorS. Przywara
Chair and Department of Vascular Surgery and Angiology, Medical University of Lublin, Lublin, Poland
Search for more papers by this authorP. Terlecki
Chair and Department of Vascular Surgery and Angiology, Medical University of Lublin, Lublin, Poland
Search for more papers by this authorA. Grabarska
Chair and Department of Biochemistry and Molecular Biology, Medical University of Lublin, Lublin, Poland
Search for more papers by this authorA. Stepulak
Chair and Department of Biochemistry and Molecular Biology, Medical University of Lublin, Lublin, Poland
Search for more papers by this authorT. Zubilewicz
Chair and Department of Vascular Surgery and Angiology, Medical University of Lublin, Lublin, Poland
Search for more papers by this authorAbstract
Objectives
Carotid endarterectomy (CEA) is a recommended treatment in the prevention of ischemic stroke. However, this procedure may cause neurological complications caused by cerebrovascular damage. While YKL-40 is a proinflammatory protein, neurofilament light polypeptide (NEFL) and brain lipid-binding protein (FABP7) are structural components of the brain. The aim of the study was to investigate YKL-40, NEFL, and FABP7 in the serum of patients undergoing CEA.
Materials and methods
The study included 25 participants who underwent CEA due to internal carotid artery stenosis. Blood samples were taken from each patient at three different intervals: prior to the surgery, 12 h after the surgery, and 48 h after the surgery. Serum levels of these brain damage markers were measured by enzyme-linked immunosorbent assay (ELISA).
Results
The study showed that the serum YKL-40 level was significantly increased 48 h after CEA when compared to the level prior to surgery and also when compared to levels 12 h after surgery. There were no statistically significant differences in serum NEFL and FABP7 levels between all three recorded measurements.
Conclusions
Data from our study showed that CEA affects serum YKL-40 but not NEFL and FABP7 levels. This implicates that YKL-40 may be a valuable serum marker of brain damage after CEA. However, the observed change in serum YKL-40 level in patients after CEA does not necessarily warrant a change in recommendations concerning the use of this treatment in patients with high-grade internal carotid artery stenosis.
References
- 1Balami JS, Sutherland BA, Edmunds LD et al. A systematic review and meta-analysis of randomized controlled trials of endovascular thrombectomy compared with best medical treatment for acute ischemic stroke. Int J Stroke 2015; 10: 1168–78.
- 2Kastrup J. Can YKL-40 be a new inflammatory biomarker in cardiovascular disease? Immunobiology 2012; 217: 483–91.
- 3Bonneh-Barkay D, Wang G, Starkey A, Hamilton RL, Wiley CA. In vivo CHI3L1 (YKL-40) expression in astrocytes in acute and chronic neurological diseases. J Neuroinflammation 2010; 7: 34.
- 4Choi JH, Pile-Spellman J, Brisman JL. US nationwide trends in carotid revascularization: hospital outcome and predictors of outcome from 1998 to 2007. Acta Neurol Scand 2014; 129: 85–93.
- 5Gupta N, Corriere MA, Dodson TF et al. The incidence of microemboli to the brain is less with endarterectomy than with percutaneous revascularization with distal filters or flow reversal. J Vasc Surg 2011; 53: 316–22.
- 6Ballesteros-Pomar M, Alonso-Argüeso G, Tejada-García J, Vaquero-Morillo F. Cerebral hyperperfusion syndrome in carotid revascularization surgery. Rev Neurol 2012; 55: 490–8.
- 7Backhaus R, Boy S, Fuchs K, Ulrich B, Schuierer G, Schlachetzki F. Hyperperfusion syndrome after MCA embolectomy - a rare complication? Am J Case Rep 2013; 14: 513–7.
- 8Holm J, Nilsson V, Waters N, Waters S, Jonsson O. Production of free radicals measured by spin trapping during operations for stenosis of the carotid artery. Eur J Surg 2001; 167: 4–9.
- 9Bjørnbak C, Brøchner C, Larsen LA, Johansen JS, Møllgård K. Brain barriers and a subpopulation of astroglial progenitors of developing human forebrain are immunostained for the glycoprotein YKL-40. J Histochem Cytochem 2014; 62: 369–88.
- 10Craig-Schapiro R, Perrin RJ, Roe CM et al. YKL-40: a novel prognostic fluid biomarker for preclinical Alzheimer's disease. Biol Psychiatry 2010; 68: 903–12.
- 11Kester MI, Teunissen CE, Sutphen C et al. Cerebrospinal fluid VILIP-1 and YKL-40, candidate biomarkers to diagnose, predict and monitor Alzheimer's disease in a memory clinic cohort. Alzheimers Res Ther 2015; 7: 59.
- 12Østergaard C, Johansen JS, Benfield T, Price PA, Lundgren JD. YKL-40 is elevated in cerebrospinal fluid from patients with purulent meningitis. Clin Diagn Lab Immunol 2002; 9: 598–604.
- 13Bonneh-Barkay D, Zagadailov P, Zou H et al. YKL-40 expression in traumatic brain injury: an initial analysis. J Neurotrauma 2010; 27: 1215–23.
- 14Gállego Pérez-Larraya J, Paris S, Idbaih A et al. Diagnostic and prognostic value of preoperative combined GFAP, IGFBP-2, and YKL-40 plasma levels in patients with glioblastoma. Cancer 2014; 120: 3972–80.
- 15Petzold A. Neurofilament phosphoforms: surrogate markers for axonal injury, degeneration and loss. J Neurol Sci 2005; 233: 183–98.
- 16Lee MK, Cleveland DW. Neurofilament function and dysfunction: involvement in axonal growth and neuronal disease. Curr Opin Cell Biol 1994; 6: 34–40.
- 17Lariviere RC, Julien JP. Functions of intermediate filaments in neuronal development and disease. J Neurobiol 2004; 58: 131–48.
- 18Trentini A, Comabella M, Tintoré M et al. N-acetylaspartate and neurofilaments as biomarkers of axonal damage in patients with progressive forms of multiple sclerosis. J Neurol 2014; 261: 2338–43.
- 19Gaiottino J, Norgren N, Dobson R et al. Increased neurofilament light chain blood levels in neurodegenerative neurological diseases. PLoS ONE 2013; 8: e75091.
- 20Tortelli R, Ruggieri M, Cortese R et al. Elevated cerebrospinal fluid neurofilament light levels in patients with amyotrophic lateral sclerosis: a possible marker of disease severity and progression. Eur J Neurol 2012; 19: 1561–7.
- 21Steinacker P, Feneberg E, Weishaupt J et al. Neurofilaments in the diagnosis of motoneuron diseases: a prospective study on 455 patients. J Neurol Neurosurg Psychiatry 2016; 87: 12–20.
- 22Liu RZ, Mita R, Beaulieu M, Gao Z, Godbout R. Fatty acid binding proteins in brain development and disease. Int J Dev Biol 2010; 54: 1229–39.
- 23Matsumata M, Inada H, Osumi N. Fatty acid binding proteins and the nervous system: their impact on mental conditions. Neurosci Res 2016; 102: 47–55.
- 24Ebrahimi M, Yamamoto Y, Sharifi K et al. Astrocyte-expressed FABP7 regulates dendritic morphology and excitatory synaptic function of cortical neurons. Glia 2016; 64: 48–62.
- 25Kipp M, Clarner T, Gingele S et al. Brain lipid binding protein (FABP7) as modulator of astrocyte function. Physiol Res 2011; 60(Suppl 1): 49–60.
- 26Morihiro Y, Yasumoto Y, Vaidyan LK, Suzuki M et al. Fatty acid binding protein 7 as a marker of glioma stem cells. Pathol Int 2013; 63: 546–53.
- 27Komoribayashi N, Ogasawara K, Kobayashi M et al. Cerebral hyperperfusion after carotid endarterectomy is associated with preoperative hemodynamic impairment and intraoperative cerebral ischemia. J Cereb Blood Flow Metab 2006; 26: 878–84.
- 28Capoccia L, Speziale F, Gazzetti M et al. Comparative study on carotid revascularization (endarterectomy vs stenting) using markers of cellular brain injury, neuropsychometric tests, and diffusion-weighted magnetic resonance imaging. J Vasc Surg 2010; 51: 584–91.
- 29Brightwell RE, Sherwood RA, Athanasiou T, Hamady M, Cheshire NJ. The neurological morbidity of carotid revascularisation: using markers of cellular brain injury to compare CEA and CAS. Eur J Vasc Endovasc Surg 2007; 34: 552–60.
- 30Coull BM. Inflammation and stroke: introduction. Stroke 2007; 38: 631.
- 31Szigeti K, Horváth I, Veres DS et al. A novel SPECT-based approach reveals early mechanisms of central and peripheral inflammation after cerebral ischemia. J Cereb Blood Flow Metab 2015; 35: 1921–9.
- 32Xu X, Ma H, Xu J et al. Elevation in circulating YKL-40 concentration in patients with cerebrovascular disease. Bosn J Basic Med Sci 2014; 14: 120–4.
- 33Park HY, Jun CD, Jeon SJ et al. Serum YKL-40 levels correlate with infarct volume, stroke severity, and functional outcome in acute ischemic stroke patients. PLoS ONE 2012; 7: e51722.
- 34Jiang YX, Zhang GH, Wang ZM, Yang H. Serum YKL-40 levels as a prognostic factor in patients with intracerebral hemorrhage. Clin Biochem 2014; 47: 302–6.
- 35Michelsen AE, Rathcke CN, Skjelland M et al. Increased YKL-40 expression in patients with carotid atherosclerosis. Atherosclerosis 2010; 211: 589–95.
- 36Rana OR, Schröder JW, Baukloh JK et al. Neurofilament light chain as an early and sensitive predictor of long-term neurological outcome in patients after cardiac arrest. Int J Cardiol 2013; 168: 1322–7.
- 37Singh P, Yan J, Hull R et al. Levels of phosphorylated axonal neurofilament subunit H (pNfH) are increased in acute ischemic stroke. J Neurol Sci 2011; 304: 117–21.
- 38Sellner J, Patel A, Dassan P, Brown MM, Petzold A. Hyperacute detection of neurofilament heavy chain in serum following stroke: a transient sign. Neurochem Res 2011; 36: 2287–91.
- 39Zimmermann-Ivol CG, Burkhard PR, Le Floch-Rohr J, Allard L, Hochstrasser DF, Sanchez JC. Fatty acid binding protein as a serum marker for the early diagnosis of stroke: a pilot study. Mol Cell Proteomics 2004; 3: 66–72.
- 40Boneva NB, Mori Y, Kaplamadzhiev DB et al. Differential expression of FABP 3, 5, 7 in infantile and adult monkey cerebellum. Neurosci Res 2010; 68: 94–102.
- 41Wunderlich MT, Hanhoff T, Goertler M et al. Release of brain-type and heart-type fatty acid-binding proteins in serum after acute ischaemic stroke. J Neurol 2005; 252: 718–24.
- 42Tso AW, Lam TK, Xu A et al. Serum adipocyte fatty acid-binding protein associated with ischemic stroke and early death. Neurology 2011; 76: 1968–75.
- 43Ma D, Zhang M, Mori Y et al. Cellular localization of epidermal type and brain-type fatty acid-binding proteins in adult hippocampus and their response to cerebral ischemia. Hippocampus 2010; 20: 811–9.
